Zanzalintinib

Zanzalintinib

Zanzalintinib is a small molecule inhibitor that is primarily used in the field of oncology for the treatment of various types of cancer. It is a type of tyrosine kinase inhibitor, which works by blocking the action of a specific enzyme known as tyrosine kinase that contributes to the growth and spread of cancer cells.

Mechanism of Action

Zanzalintinib functions by inhibiting the activity of tyrosine kinase, an enzyme that plays a crucial role in the signaling pathways that regulate cellular processes such as growth, division, and the survival of cells. By blocking the action of this enzyme, Zanzalintinib can prevent the proliferation and spread of cancer cells, thereby slowing down the progression of the disease.

Clinical Use

Zanzalintinib is currently being investigated for its potential use in the treatment of various types of cancer, including lung cancer, breast cancer, and colorectal cancer. Preliminary studies have shown promising results, with Zanzalintinib demonstrating significant anti-tumor activity in both in vitro and in vivo models.

Side Effects

As with all medications, Zanzalintinib may cause side effects in some patients. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include liver damage and cardiotoxicity. Patients should be monitored closely for these side effects during treatment with Zanzalintinib.

Future Research

Further research is needed to fully understand the potential benefits and risks of Zanzalintinib in the treatment of cancer. Ongoing clinical trials are investigating the drug's efficacy and safety profile in a variety of cancer types and patient populations.